Screener
Celldex Therapeutics CLDX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Depreciation and amortization | 1,756 | 1,740 |
| Amortization and premium of marketable securities, net | (2,328) | (3,955) |
| Loss on sale or disposal of assets | 4 | 6 |
| Stock-based compensation expense | 16,931 | 18,507 |
| Changes in operating assets and liabilities: | ||
| Accounts and other receivables | 1,785 | 610 |
| Prepaid and other current assets | 5,116 | 3,020 |
| Other assets | (2,076) | 447 |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's stock-based comp?
- Celldex Therapeutics (CLDX) reported stock-based comp of $8.41M in Q2 2026.
- How has Celldex Therapeutics's stock-based comp changed year-over-year?
- Celldex Therapeutics's stock-based comp decreased by 8.5% year-over-year, from $9.19M to $8.41M.
- What is the long-term trend for Celldex Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Celldex Therapeutics's stock-based comp has grown at a 41.8% compound annual growth rate (CAGR), from $8.95M to $36.22M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Celldex Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude